DBP International: Signed a collaboration partnership agreement with Alexavi for commercialization of Temodex®
Double Bond Pharmaceutical International AB (publ) (“DBP” or “Double Bond”) has entered into a collaborative partnership with Alexavi Ltd (“Alexavi”). This is a major step in Double Bond’s development process and marks the company’s commitment to move forward towards approval and commercialisation of Temodex® program, for the treatment of Glioblastoma. This collaboration will open up accessibility to a ground-breaking treatment paradigm in this therapeutic area. Alexavi will be managing an Early Access to Treatment program on behalf of Double Bond to raise awareness of the treatment’s